Compared with the WT-AKI-CKD group, in the C3−/−-AKI-CKD group, TEM shows improved podocyte fusion, with significantly increased the level of podocyte functional protein and decreased the level of TRPC6, consequently improving proteinuria and renal function. This evidence concerns the gene TRPC6 and chronic kidney disease.